Integrated Wealth Concepts LLC Purchases 10,616 Shares of Bristol-Myers Squibb (NYSE:BMY)

Integrated Wealth Concepts LLC lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 19.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,346 shares of the biopharmaceutical company's stock after buying an additional 10,616 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Bristol-Myers Squibb were worth $3,696,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wealthspire Advisors LLC raised its position in Bristol-Myers Squibb by 0.6% during the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after acquiring an additional 170 shares in the last quarter. Edmp Inc. raised its position in Bristol-Myers Squibb by 0.4% during the fourth quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock worth $2,353,000 after acquiring an additional 171 shares in the last quarter. Trust Point Inc. raised its position in Bristol-Myers Squibb by 1.9% during the fourth quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company's stock worth $533,000 after acquiring an additional 172 shares in the last quarter. Bedel Financial Consulting Inc. raised its position in Bristol-Myers Squibb by 3.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock worth $340,000 after acquiring an additional 175 shares in the last quarter. Finally, Horst & Graben Wealth Management LLC raised its position in Bristol-Myers Squibb by 2.4% during the fourth quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company's stock worth $426,000 after acquiring an additional 179 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. UBS Group dropped their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company increased their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $58.00.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Price Performance

NYSE BMY traded up $0.75 on Tuesday, hitting $49.21. 19,790,282 shares of the company's stock were exchanged, compared to its average volume of 12,964,894. The stock has a 50-day moving average of $56.11 and a 200-day moving average of $56.45. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The stock has a market cap of $100.13 billion, a price-to-earnings ratio of -11.13, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the prior year, the company earned ($4.40) earnings per share. The company's quarterly revenue was down 5.6% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.04%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's payout ratio is presently 92.88%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.